Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07170072 · ClinicalTrials.gov registry record

Shelter HArm Reduction Evaluation

A clinical trial of Overdose and Harm Reduction, sponsored by NYU Langone Health.

Recruiting
Registry status
80
Enrollment target
1
Study location

NCT07170072: Recruiting study of Overdose and Harm Reduction, sponsored by NYU Langone Health.

NCT07170072 is a study of Overdose and Harm Reduction that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 80 participants, below the 260-participant average among 13 other Overdose trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07170072, a study of Overdose and Harm Reduction, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The proposed study will use mixed methods research to examine overdose and other health-related impacts of harm reduction initiatives in NYC homeless shelters.

Conditions Studied

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-07-01
Est. Completion 2026-09-30
NYU Langone Health

1,164 total trials

What NCT07170072 shows while recruiting

NCT07170072 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 260-participant average among 13 other Overdose trials with a reported enrollment target (69% lower).

The record links to 2 conditions, with Overdose appearing as the primary indexed condition, and to 0 interventions.

NCT07170072 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07170072 about?

NCT07170072 is a clinical study titled "Shelter HArm Reduction Evaluation". The proposed study will use mixed methods research to examine overdose and other health-related impacts of harm reduction initiatives in NYC homeless shelters.

What is the current status of trial NCT07170072?

This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2025-07-01. Estimated completion is 2026-09-30.

What conditions does trial NCT07170072 study?

This clinical trial studies the following conditions: Overdose, Harm Reduction.

Who is sponsoring clinical trial NCT07170072?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07170072 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overdose

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07170072's enrollment target sits among peer trials

80 9th of 13 higher than 5 of 13 other Overdose trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Overdose trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07170072, the US trial registry maintained by the National Library of Medicine. NCT07170072 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.